BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38626012)

  • 21. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis.
    Kwon YD; Ko KO; Lim JW; Cheon EJ; Song YH; Yoon JM
    J Korean Med Sci; 2019 Jun; 34(23):e165. PubMed ID: 31197983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.
    Poustchi H; Alaei-Shahmiri F; Aghili R; Nobarani S; Malek M; Khamseh ME
    Arch Iran Med; 2021 Mar; 24(3):177-186. PubMed ID: 33878875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Tovo CV; Villela-Nogueira CA; Leite NC; Panke CL; Port GZ; Fernandes S; Buss C; Coral GP; Cardoso AC; Cravo CM; Calçado FL; Rezende GFM; Ferreira FC; Araujo-Neto JM; Perez RM; Moraes-Coelho HS; de Mattos AA
    Ann Hepatol; 2019; 18(3):445-449. PubMed ID: 31031166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome and female gender, but not methotrexate, are the important associations of significant liver fibrosis in patients with moderate-to-severe psoriasis as detected by transient elastography.
    Mahajan R; Dogra S; Handa S; Razmi TM; Narang T; Rathi S; Dhiman RK; Saikia B; Karim A
    Indian J Dermatol Venereol Leprol; 2020; 86(6):649-655. PubMed ID: 32643632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
    Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
    Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Prevalence of Advanced Liver Fibrosis Among Patients With Type 2 Diabetes Mellitus: A Single-Centre Experience in Penang, Malaysia.
    Lee XH; Nor LM; Ang CS; Yeow TP; Lim SL
    J ASEAN Fed Endocr Soc; 2023; 38(1):52-61. PubMed ID: 37252406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
    J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.
    Assarrar I; Messaoudi N; Ongoth FEM; Abdellaoui W; Malki A; Rouf S; Abda N; Ismaili Z; Latrech H
    Rev Diabet Stud; 2022 Sep; 18(3):140-145. PubMed ID: 36309775
    [No Abstract]   [Full Text] [Related]  

  • 32. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis.
    Gisondi P; Barba E; Girolomoni G
    J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):282-7. PubMed ID: 26537011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver stiffness accuracy by magnetic resonance elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort.
    Lara Romero C; Liang JX; Fernández Lizaranzazu I; Ampuero Herrojo J; Castell J; Del Prado Alba C; Domínguez Pascual I; Romero Gómez M
    Rev Esp Enferm Dig; 2023 Apr; 115(4):162-167. PubMed ID: 35791792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
    Ciardullo S; Perseghin G
    Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative.
    Pitisuttithum P; Chan WK; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Dan YY; Imajo K; Nakajima A; Ho KY; Goh KL; Wong VW; Treeprasertsuk S
    World J Gastroenterol; 2020 May; 26(19):2416-2426. PubMed ID: 32476802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing the Use of the Gamma-Glutamyl Transpeptidase-to-Platelet Ratio and Transient Elastography to Identify Liver Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease.
    Zhang GL; Xu SC; Zeng J; Chen Z; Li YP; Zhang T; Gao ZL
    Dis Markers; 2019; 2019():2585409. PubMed ID: 31885733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
    Ciardullo S; Monti T; Perseghin G
    Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis.
    Méndez-Sánchez N; Cerda-Reyes E; Higuera-de-la-Tijera F; Salas-García AK; Cabrera-Palma S; Cabrera-Álvarez G; Cortez-Hernández C; Pérez-Arredondo LA; Purón-González E; Coronado-Alejandro E; Panduro A; Rodríguez-Hernández H; Cruz-Ramón VC; Valencia-Rodríguez A; Qi X; Hamdan-Pérez N; Aguilar-Olivos NE; Barranco-Fragoso B; Ramírez-Pérez O; Vera-Barajas A
    F1000Res; 2020; 9():56. PubMed ID: 32595949
    [No Abstract]   [Full Text] [Related]  

  • 40. Shear Wave Elastography Reveals a High Prevalence of NAFLD-related Fibrosis even in Type 1 Diabetes.
    Meyer G; Dauth N; Grimm M; Herrmann E; Bojunga J; Friedrich-Rust M
    Exp Clin Endocrinol Diabetes; 2022 Aug; 130(8):532-538. PubMed ID: 34784620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.